H. Saegesser

Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.

J. Reichen, M. Neef, M. Ledermann, 2006, Journal of hepatology.

Basic Studies

A. de Gottardi, M. Ledermann, H. Saegesser, 2005 .

Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term.

J. Reichen, L. Decosterd, M. Neef, 2006, Journal of hepatology.

Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis.

C. Hellerbrand, M. Ledermann, H. Saegesser, 2010, Journal of hepatology.

Endothelial nitric oxide synthase is not essential for the development of fibrosis and portal hypertension in bile duct ligated mice

A. de Gottardi, M. Ledermann, H. Saegesser, 2005, Liver international : official journal of the International Association for the Study of the Liver.

Corrigendum to “Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis” [J Hepatol 45 (2006) 786–796]

J. Reichen, M. Neef, M. Ledermann, 2007 .